GLP-1 receptor agonists vs DPP-4 inhibitors and neuropathic complications in type 2 diabetes
- Design
- Retrospective cohort · 19770 participants · Hard outcome
- Match to healthy normal-weight adults aged 55–75
- Different population[Auto] Participants had type 2 diabetes (age/BMI not reported in abstract).
- Could weight loss explain it?
- Possibly[Auto] Participants had obesity and/or type 2 diabetes and the abstract does not separate direct drug effects from weight loss or glycaemic improvement.
- Study tier
- Study tier 3[Auto] Observational design; confounding by indication and healthy-user effects cannot be excluded (auto-provisional).
- Assessment
- Version 1 · automatic, not yet reviewed by a person · Sep 13, 2026
Study facts come from the paper. Population match, weight-loss explanation and study tier are our judgments, made against the reference group of healthy normal-weight adults aged 55–75.
[Auto, unreviewed; last sentences of abstract] [DISCUSSION] In T2DM patients with neuropathy, GLP-1 RA therapy was associated with lower risk of diabetic foot ulcers and higher Charcot neuroarthropathy risk compared with DPP-4 inhibitors, while amputation and osteomyelitis risks were similar. These findings support further study of GLP-1 RAs in this population and highlight the need for careful foot monitoring during therapy.
01Findings
What the study reported
- Drugs
- Class unspecified
- Comparator
- DPP-4 inhibitors
- Primary outcome
- Not extracted
- Effect
- Not extracted
- 95% confidence interval
- Not extracted
- Follow-up
- 2 years
- Adverse events
- Not extracted
- Limitations
- Auto-classified from abstract only; effect estimates, adverse events and limitations not extracted. Requires manual review.
Who was studied
- Diabetes status
- type 2 diabetes present (all or most)
- Sample size
- 19770
Study quality details
- Study design
- Retrospective cohort
- Sample size
- 19770
- Randomization
- no
- Blinding
- not stated
- Comparator
- active comparator
- Follow up duration
- 2 years
- Outcome type
- hard
- Replication
- not assessed (auto)
- Consistency with other evidence
- not assessed (auto)
- Population applicability
- INDIRECT
- Statistical precision
- CI reported: 95% CI 0
- Risk of bias
- not assessed (auto)
- Funding conflicts
- unclear
- Peer review status
- yes
02Funding
Funding and conflicts
- Funding
- not reported in abstract
- Industry funded
- Unclear
- Manufacturer
- None identified
- Sponsor role
- not reported in abstract
- Author conflicts
- Declarations. Conflicts of interest: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Ethical Publication and Informed Consent Statement: This study was determined to be exempt from review by the Howard University Hospitals Institutional Review Board (IRB), as it involved the retrospective analysis of de-identified patient data obtained from the TriNetX Global Collaborative Network. No identifiable private information was collected or recorded, and there was no direct interaction with patients. As such, the research qualifies for exemption under 45 CFR 46.104(d)(4). Informed consent was not required. All research activities were carried out in accordance with the guidelines and regulations of the Howard University Hospitals Institutional Review Board and in compliance with the ethical principles outlined in the 1964 Declaration of Helsinki and its later amendments.
- Independent replication
- unknown
Funding is shown on every study and never used to score it.
04Source
The source, as retrieved
Abstract
[INTRODUCTION] Diabetic peripheral neuropathy is a debilitating complication of type 2 diabetes mellitus (T2DM) associated with foot ulceration, amputation, Charcot neuroarthropathy, and reduced quality of life. Although glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 (DPP-4) inhibitors are widely used therapies for T2DM, their comparative effects on neuropathy-related lower-extremity complications remain unclear. [OBJECTIVE] To compare diabetic foot ulcers, lower-extremity amputations, foot/ankle osteomyelitis, Charcot neuroarthropathy, and all-cause mortality in T2DM patients with neuropathy treated with GLP-1 RAs versus DPP-4 inhibitors. [METHODS] Using the TriNetX US Collaborative Network, we identified adults with T2DM and diabetic neuropathy, unspecified (ICD-10-CM E11.40), initiating either a GLP-1 RA or a DPP-4 inhibitor. After exclusions and 1:1 propensity score matching for demographics, comorbidities, and medications, 19,770 patients per cohort were balanced. Outcomes were assessed over 1 year and 2 years using Kaplan-Meier and Cox proportional hazards models, with Bonferroni correction (p < 0.01). [RESULTS] After matching, GLP-1 RAs were associated with a 1-year lower risk of diabetic foot ulcers (2.2% vs 2.7%; HR 0.813, 95% CI 0.716-0.922) and lower all-cause mortality, though the mortality finding was interpreted as hypothesis-generating. Amputation (0.5% vs 0.5%; HR 1.073, 95% CI 0.810-1.421) and foot/ankle osteomyelitis (0.4% vs 0.4%; HR 0.978, 95% CI 0.708-1.349) rates were similar. Charcot neuroarthropathy incidence was higher with GLP-1 RAs (0.3% vs 0.2%; HR 1.993, 95% CI 1.297-3.064). [DISCUSSION] In T2DM patients with neuropathy, GLP-1 RA therapy was associated with lower risk of diabetic foot ulcers and higher Charcot neuroarthropathy risk compared with DPP-4 inhibitors, while amputation and osteomyelitis risks were similar. These findings support further study of GLP-1 RAs in this population and highlight the need for careful foot monitoring during therapy.
Where this record came from
| Source | Retrieved | Identifier |
|---|---|---|
| pubmed | Sep 13, 2026 | 42704495 first ingestion |